Lian SGP Holding Pte. Ltd., a Singapore-based entity wholly owned by China’s Livzon Pharmaceutical Group Inc., has acquired a controlling stake in Vietnam’s pharma giant Imexpharm (HoSE: IMP) ...

Imexpharm, a leader in Vietnam’s pharmaceutical industry, is entering a new growth phase with a focus on the production of invented drugs, leveraging advanced technology to meet stringent ...

Imexpharm Joint Stock Pharmaceutical Company has received the "Vietnam Pharmaceutical Star" award, which honors domestic pharmaceutical companies for significant contributions to healthcare, ...

Imexpharm Corporation announced its business results for the first half of the year (H1) on July 18, reporting a 22% year-over-year increase in net revenue and an EBITDA margin of 22%. In H1, ...

Imexpharm Corp. Imexpharm Corp. engages in the manufacture, import, export and trade of pharmaceuticals, medicinal chemicals and botanical. Its other activities include import and export of medical ...

Imexpharm Pharmaceutical Joint Stock Company is charting a significant growth trajectory by intensifying its research and development (R&D) initiatives as a strategic move to develop high-tech ...

As of 10:25:13 AM GMT+7. Market Open.

At its AGM in Ho Chi Minh City on April 22, Imexpharm approved its business plan, with earnings before interest, taxes, depreciation, and amortisation expected to rise 12.3 per cent. Profit metrics ...

Imexpharm Corp. company facts, information and financial ratios from MarketWatch.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...